Myovant’s lack of relugolix dosing options may hurt its usage in endometriosis-related pain
Topline results from relugolix’s Phase III SPIRIT 2 and SPIRIT 1 trials are expected in 1Q20 and 2Q20, respectively.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
